PD-1 Blockade in Mediastinal Gray-Zone Lymphoma

N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Lymphoma / diagnostic imaging
  • Lymphoma / drug therapy*
  • Lymphoma / metabolism
  • Male
  • Mediastinal Neoplasms / diagnostic imaging
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinal Neoplasms / metabolism
  • Nivolumab
  • Positron-Emission Tomography
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / metabolism
  • Recurrence

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab